Summit Therapeutics Shares Jump 20% on $2 Billion AstraZeneca Investment

Key Facts

1Summit Therapeutics shares surged over 20% in pre-market trading following AstraZeneca's announcement of a $2 billion investment.

2AstraZeneca's UK-listed shares rose 1.9% to a two-month high following the deal announcement.

Summit Therapeutics shares surged over 20% in pre-market trading following AstraZeneca's announcement of a $2 billion investment. Reuters reported that the strategic equity investment and clinical collaboration agreement focuses on oncology treatments, specifically the company's cancer treatment pipeline.

SMMT closed at $15.48 on September 28, 2026, while AZN closed at $166.15 on the same date. According to Invezz, AstraZeneca's UK-listed shares rose 1.9% to a two-month high following the deal, signaling institutional confidence in Summit's clinical developments.